Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy

Previously advanced lung cancer inflammation index (ALI) has been demonstrated to have prognostic utility in the stratification of patients into distinctive survival groups, but the prognostic value of ALI has never been explored in the setting of locally advanced pancreatic carcinomas (LAPC) treate...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2019-01, Vol.11, p.8807-8815
Main Authors: Topkan, Erkan, Mertsoylu, Huseyin, Ozdemir, Yurday, Sezer, Ahmet, Kucuk, Ahmet, Besen, Ali Ayberk, Ozyilkan, Ozgur, Selek, Ugur
Format: Article
Language:English
Subjects:
Abdomen
advanced lung cancer inflammation index
Analysis
Autophagy
Biochemistry
Blood tests
Cancer therapies
Carcinoma
Care and treatment
Chemotherapy
concurrent chemoradiotherapy
Development and progression
Inflammation
Locally-advanced pancreas cancer
Lung cancer
Lymphocytes
Medical imaging
Medical prognosis
Metabolism
Metastasis
Mortality
Novels
Oncology
Original Research
Pancreatic cancer
Patients
Prognosis
Radiation therapy
Sarcopenia
survival outcomes
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previously advanced lung cancer inflammation index (ALI) has been demonstrated to have prognostic utility in the stratification of patients into distinctive survival groups, but the prognostic value of ALI has never been explored in the setting of locally advanced pancreatic carcinomas (LAPC) treated with concurrent chemoradiotherapy (CCRT). Hence, we aimed to investigate the prognostic value of pre-treatment ALI in LAPC patients who underwent radical CCRT. Present retrospective cohort analysis incorporated 141 LAPC patients who received radical CCRT. Accessibility of baseline ALI cutoff(s) impacting survival outcomes was sought by receiver operating characteristic (ROC) curve analysis. Interaction between the ALI and overall- (OS) and progression-free survival (PFS) comprised our primary and secondary endpoints, respectively. At a median follow-up of 14.4 months (range: 3.2-74.2), the median PFS and OS were 7.5 (%95 CI: 5.9-9.1) and 14.6 months (%95 CI: 11.6-17.6), respectively. ROC curve analyses set the ideal ALI cutoff value at 25.3 (AUC: 75.6%; sensitivity: 72.7%; specificity: 70.3%) that exhibited significant associations with both the OS and PFS results. Patient stratification into two groups per ALI [≤25.3 (N=75) versus>25.3 (N=66)] showed that the ALI>25.3 group had significantly superior median OS (25.8 versus 11.4 months; P
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S222297